Effect of Desflurane on Cardiac Function During Cardiac Surgery: Tissue Doppler Imaging of Mitral Valve Annular Velocity

NCT ID: NCT02003885

Last Updated: 2015-03-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2015-09-30

Brief Summary

The purpose of this study is to determine desflurane's dose-dependent effect on left ventricular (LV) function in cardiac surgery. The change of tissue Doppler imaging (TDI) of lateral mitral valve annular velocity at three different desflurane concentrations would be analyzed by using intraoperative transesophageal echocardiography (TEE) in cardiac surgery patients

Detailed Description

Tissue Doppler imaging (TDI ) of mitral annular velocity during the cardiac cycle has been introduced as a reliable method for analysis of systolic and diastolic LV ling-axix function , efficacy of diastolic TDI profile, including early early relaxation (E') and atrial contraction (A') and has been suggested to be useful in predicting the postoperative clinical outcomes and the impact of isoflurane on LV diastolic function.

Desflurane is widely used in cardiac surgery patients due to its beneficial effects , but many studies have shown that desflurane reduces myocardial contractility in a dose-dependent manner, and compromises left ventricular( LV) function We hypothesized that desflurane , even at a clinical dosage, would affects intraoperative LV systolic function in a dose-dependent manner and thus produce significant changes int the TDI profiles of mitral annular velocity.

So we planned to study the changes in TDI profiles of lateral mitral annular velocity at the clinical desflurane dosage during remifentanil based anesthesia for cardiac surgery

Conditions

Valvular Heart Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Desflurane increment

increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery

Group Type: EXPERIMENTAL

increment of desflurane

Intervention Type: DRUG

After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.

After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.

Reduction of BP is managed by the increment of phenylephrine infusion

Interventions

increment of desflurane

After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.

After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.

Reduction of BP is managed by the increment of phenylephrine infusion

Intervention Type: DRUG

Other Intervention Names

Desflurane inhalation 0.5 MAC, 1.0 MAC and 1.5 MAC

Eligibility Criteria

Inclusion Criteria

• Patients undergoing cardiac surgery

Exclusion Criteria

• Low ejection fraction <50% in preoperative transthoracic echocardiography
• Atrial fibrillation
• Pacemaker
• Pericardial and infiltrative myocardial disease
• Mitral annular calcification, surgical rings, prosthetic mitral valves
• Lateral left ventricular regional wall motion abnormality
• Esophageal spasm, stricture, laceration, perforation, and diverticulum
• Diaphragmatic hernia
• History of extensive radiation to mediastinum
• Upper gastrointestinal bleeding

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Konkuk University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Tae-Yop Kim, MD PhD

Professor of Anesthesiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tae-Yop Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Konkuk University Medical Center

Locations

Konkuk University Medical Center

Seoul, Seoul, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Tae-Yop Kim, MD, PhD

Role: CONTACT

82-10-8811-6942

Facility Contacts

Seong-Ho Lee

Role: primary

20110360@kuh.ac.kr

82-2-2030-6522

Other Identifiers

KUH1160063

Identifier Type: -

Identifier Source: org_study_id